fbpx
QQQ
-2.71
348.05
-0.78%
DIA
-5.86
344.51
-1.73%
SPY
-7.07
429.04
-1.68%
TLT
+ 2.69
140.35
+ 1.88%
GLD
-0.87
166.72
-0.52%

Why Is Merck's Stock Trading Lower Today?

April 29, 2021 1:12 pm
Share to Linkedin Share to Twitter Share to Facebook Share to Print License More
Why Is Merck's Stock Trading Lower Today?

Merck & Co (NYSE:MRK) shares are trading lower after the company reported worse-than-expected EPS and sales results.

Merck reported quarterly earnings of $1.40 per share, which missed the analyst consensus estimate of $1.63. The company reported quarterly sales of $12.08 billion, which missed the analyst consensus estimate of $12.66 billion.

"While our results this quarter were impacted by the pandemic, the underlying demand for our innovative products remains strong and we remain confident in our future growth prospects," said Kenneth C. Frazier, chairman and CEO, Merck.

Merck makes pharmaceutical products to treat several conditions in a number of therapeutic areas, including cardiometabolic disease, cancer, and infections.

The stock was trading 5.4% lower at $72.93 at the time of writing. The stock has a 52-week high of $87.80 and a 52-week low of $71.72.

For the latest in financial news, exclusive stories, memes follow Benzinga on Twitter, Facebook & Instagram. For the best interviews, stock market talk & videos, subscribe to our YouTube channel.

Posted-In:

Movers Trading Ideas

Related Articles

Fusion Pharma's Stock Moves Higher As Radiopharmaceutical Candidate Shows Early Promising Action In Solid Tumor Study

Oncolytics Pelareorep/Pembrolizumab Combo Therapy Shows Anti-Cancer Activity In Pancreatic Cancer

Immutep Stock Gains on Encouraging Data from Early-Stage Solid Cancer Studies

BofA Says GlaxoSmithKline's Decision To Halt Feladilimab Studies Is Disappointing

GlaxoSmithKline plc (NYSE: GSK) announced the termination of the Phase II and Phase III studies of feladilimab, its ICOS receptor agonist in head and neck cancer. This comes as a disappointment, as the candidate could potentially address a multimillion-dollar market, according to BofA Securities. read more